Natalizumab strongly suppresses cortical pathology in relapsing–remitting multiple sclerosis

Abstract

Natalizumab treatment significantly decreases cortical lesion accumulation and cortical atrophy progression in severe relapsing-remitting MS. While supporting the inflammatory origin of cortical lesions, our results highlight the significant impact of natalizumab on cortical pathology.